metformin has been researched along with semaglutide in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (48.28) | 24.3611 |
| 2020's | 15 (51.72) | 2.80 |
| Authors | Studies |
|---|---|
| Aroda, VR; Axelsen, M; Bain, SC; Cariou, B; DeVries, JH; Piletič, M; Rose, L; Rowe, E | 1 |
| Anderson, TW; Derving Karsbøl, J; Golor, G; Hausner, H; Holst, AG; Jacobsen, JB; Wagner, FD | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Kokkinos, A; Liatis, S; Liberopoulos, E; Tentolouris, N | 1 |
| Carmona-Nimo, E; Castilla-Guerra, L; Fernandez-Moreno, MDC; Leon-Jimenez, D | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Druyts, E; Kanters, S; Lopes, S; Popoff, E; Sharma, R; Vrazic, H; Wilkinson, L | 2 |
| Arechavaleta, R; Bain, SC; Bogdański, P; Comlekci, A; Consoli, A; Deerochanawong, C; Dungan, K; Faingold, MC; Farkouh, ME; Franco, DR; Gram, J; Guja, C; Husain, M; Jeppesen, OK; Joshi, P; Malek, R; Merino-Torres, JF; Mosenzon, O; Nauck, MA; Pedersen, SD; Sheu, WH; Silver, RJ; Strange, M; Tack, CJ; Tandon, N; Thomsen, M | 1 |
| Allison, D; Birkenfeld, AL; Blicher, TM; Davies, M; Deenadayalan, S; Jacobsen, JB; Rosenstock, J; Serusclat, P; Violante, R; Watada, H | 1 |
| Hirsch, IB | 1 |
| Anderson, TW; Borregaard, J; Bækdal, TA; Hansen, CW; Thomsen, M | 1 |
| Lipscombe, LL | 1 |
| Araki, E; Aroda, VR; Buse, JB; Cariou, B; Harris, SB; Hoff, ST; Pedersen, KB; Tarp-Johansen, MJ; Zinman, B | 1 |
| Capehorn, MS; Catarig, AM; Furberg, JK; Janez, A; Marre, M; Price, HC; Tadayon, S; Vergès, B | 1 |
| Scheen, AJ | 1 |
| Bain, SC; Chudleigh, RA | 1 |
| Capehorn, MS; Catarig, AM; Johansen, P; Lawson, J; Lingvay, I; Paine, A; Sandberg, A; Shaw, R | 1 |
| Piszczatoski, C; Powell, J; Taylor, JR | 1 |
| Alsumali, A; Briggs, A; Davies, G; Kowal, S; Lautsch, D; Li, Q; Rajpathak, S; Wehler, E | 1 |
| Bergman, BK; Brown, K; Cui, X; Davies, MJ; Fernández Landó, L; Frías, JP; Liu, B; Pérez Manghi, FC; Rosenstock, J | 1 |
| Gallwitz, B; Giorgino, F | 1 |
| Bech, PG; Fridhammar, A; Liu, A; Miresashvili, N; Nilsson, A; Stafford, S; Willis, M | 1 |
| Bain, S; Consoli, A; De Remigis, A; Husain, M; Pettersson Meyer, AS; Rasmussen, S | 1 |
| Jacob, S; Kaltoft, MS; Kellerer, M; Lawson, J; Nielsen, LL; Strojek, K; Tabak, Ö | 1 |
| Cheng, AY; Hoog, M; Levine, JA; Mody, R; Pantalone, KM; Patel, H; Sapin, H; Vadher, K | 1 |
| Buse, JB; Cziraky, M; Harty, BJ; Mitchell, J; Nordahl Christensen, H; Soule, BP; Willey, VJ; Zacherle, E | 1 |
| Ahmed, M; Butt, TS; Ganesan, S; Khatri, M; Kumar, S; Madhurita, F; Nageeta, F; Patel, T; Sohail, R; Varrassi, G; Zafar, M; Zafar, W; Zaman, MU | 1 |
| Wu, Y; Yuan, S | 1 |
| Bain, S; Berry, S; Hunt, B; Malkin, SJP; Ren, H | 1 |
11 review(s) available for metformin and semaglutide
| Article | Year |
|---|---|
Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Pioglitazone; Sodium-Glucose Transporter 2 | 2018 |
Antidiabetic drugs and stroke risk. Current evidence.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thiazolidinediones | 2018 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2020 |
Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Renal Insufficiency, Chronic | 2020 |
Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Topics: Administration, Oral; Body Weight; Cardiovascular Diseases; Comorbidity; Decision Making; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Hemoglobins; Humans; Hypoglycemia; Hypoglycemic Agents; Injections, Subcutaneous; Liver; Metformin; Obesity; Renal Insufficiency, Chronic; Research Design; Risk; Stomach | 2021 |
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin | 2022 |
Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate | 2023 |
Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Topics: Body Mass Index; Comorbidity; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; East Asian People; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Quality-Adjusted Life Years; Treatment Outcome | 2023 |
10 trial(s) available for metformin and semaglutide
| Article | Year |
|---|---|
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, mul
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged | 2017 |
Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.
Topics: Adolescent; Adult; Atorvastatin; Cross-Over Studies; Digoxin; Drug Interactions; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Warfarin; Young Adult | 2017 |
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Renal Insufficiency, Chronic | 2019 |
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Topics: Administration, Oral; Adult; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds | 2019 |
Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
Topics: Administration, Oral; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Caprylates; Cardiotonic Agents; Case-Control Studies; Cross-Over Studies; Digoxin; Drug Interactions; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Healthy Volunteers; Humans; Hypoglycemic Agents; Lisinopril; Male; Metformin; Middle Aged; Warfarin | 2019 |
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nausea; Treatment Outcome; Weight Loss | 2019 |
Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Liraglutide; Male; Metformin; Middle Aged; Treatment Outcome | 2020 |
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Male; Metformin; Middle Aged; Nausea; Weight Loss | 2021 |
Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.
Topics: Canada; Canagliflozin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years | 2022 |
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Aspart; Insulin Glargine; Metformin; Treatment Outcome | 2022 |
8 other study(ies) available for metformin and semaglutide
| Article | Year |
|---|---|
The Future of the GLP-1 Receptor Agonists.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Metformin; Sitagliptin Phosphate | 2019 |
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Metformin; Sitagliptin Phosphate | 2019 |
SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Metformin; Sodium-Glucose Transporter 2 | 2019 |
Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate | 2021 |
Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
Topics: Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Gastric Inhibitory Polypeptide; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Treatment Outcome | 2022 |
Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insulins; Metformin; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; United Kingdom | 2023 |